Compare IHD & MBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IHD | MBOT |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.9M | 114.9M |
| IPO Year | N/A | 2000 |
| Metric | IHD | MBOT |
|---|---|---|
| Price | $7.72 | $1.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 128.9K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | ★ 10.32% | N/A |
| EPS Growth | N/A | ★ 60.27 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $116,887.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $119.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.75 | $1.60 |
| 52 Week High | $8.14 | $4.62 |
| Indicator | IHD | MBOT |
|---|---|---|
| Relative Strength Index (RSI) | 53.40 | 42.92 |
| Support Level | $7.13 | $1.65 |
| Resistance Level | $8.07 | $2.21 |
| Average True Range (ATR) | 0.21 | 0.08 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 63.16 | 28.12 |
Voya Emerging Markets High Dividend Equity Fund is a diversified closed-end management investment company. Its primary investment objective is to provide total return through a combination of current income, capital gains, and capital appreciation. The company seeks to achieve its investment objectives by investing principally in a portfolio of equity securities, and issuers in emerging market countries. The Fund will also normally seek to secure gains and enhance the stability of returns over a market cycle by writing (selling) call options on selected exchange-traded funds (ETFs) and/or international, regional, or country indices of equity securities, and/or on equity securities.
Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, the company has developed the LIBERTY Endovascular Robotic Surgical System, a fully disposable robot for various endovascular interventional procedures. The company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery.